Identity and Access Management Software Provider BIO-key Reports Q1’24 Revenue of $2.2M and Positive Operating Cash Flow; Hosts Investor Call Tuesday, 10am ET

In this article:
BIO-key International, Inc.BIO-key International, Inc.
BIO-key International, Inc.

HOLMDEL, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its first quarter ended March 31, 2024 (Q1’24). Note, BIO-key’s results for the first three quarters of 2023 were restated at year-end and filed with the Company’s 2023 Form 10-K, and as a result Q1’23 comparisons in this release have been restated. BIO-key will host an investor call Tuesday, June 18th at 10:00am ET (details below).

Q1 Financial Highlights

  • Q1’24 revenues of $2.2M were in line with Q1’23 and increased 19.5% from Q4’23 revenues of $1.8M

  • Gross profit increased to $1.9M (86.3% gross margin) from $0.9M (40% gross margin) in Q1’23, reflecting the impact of a Q1’23 $0.5M hardware inventory reserve, as well as higher software license fees in Q1’23 due to higher royalty payments on third-party software solutions.

  • Operating expenses were reduced over $0.2M in Q1’24 versus Q1’23, reflecting ongoing cost management initiatives.

  • BIO-key reported a Q1’24 net loss of $0.5M compared to a net loss of $1.7M in Q1’23

  • Cash generated from operating activities improved to $0.3M in Q1’24 vs. a $1.9M cash used in Q1’23, principally reflecting the benefit of a $1.5M cash payment in Q1’24 for 2-year extension/expansion of biometric technology license with a long-term financial services customer.

Other Recent Software Deployments:

Commentary
BIO-key CEO, Mike DePasquale commented, “BIO-key delivered solid progress in Q1’24, achieving positive cash flow from operations in the period, on revenue of $2.2M, representing a 19.5% increase over Q4’23 and roughly flat with the year-ago period. The current-year period benefitted from the expanded deployment of BIO-key’s biometric client identification system used by a long-standing financial services client. We also further trimmed operating expenses during Q1’24, contributing to our improved bottom-line performance.

“We remain focused on driving revenue growth and progressing our business to profitability and positive cash flow over the next several quarters. We are encouraged by the traction building within our global Channel Alliance Partner program and with the larger-scale customer dialogues in which we are engaged through our in-house direct sales effort. We believe the cybersecurity landscape continues to provide a compelling backdrop for our company, as we expect it will generate increased demand for secure, zero-trust Identity and Access Management solutions that are the core of our offerings.

“Tailwinds that we expect to support our growth include a growing proportion of enterprises that are moving IT infrastructure to the cloud as well as increasingly stringent regulatory standards as well as cyber insurance underwriting requirements, much of which are now mandating multi-factor authentication or passwordless security solutions that BIO-key is well positioned to provide on a very competitive basis.

“We are also very bullish on the growth potential for passkey authentication this year and going forward. We entered this market with the recent launch of Passkey:YOU – BIO-key’s unique passwordless authentication solution that leverages our strength in biometric security to deliver secure passkeys without the use of phones or hardware tokens.

“We continue to pursue large enterprise opportunities through our direct sales channel, looking to build on recent successes in this area. We are also working to support our global channel partners in developing new customer opportunities to further build our end-user base. Our efforts have forged a growing base of high-margin annually recurring revenues (ARRs) and believe there is substantial potential to grow our ARR base moving forward. At the same time, we will continue to pursue cost reduction opportunities to accelerate our path to profitability and positive cash flow. We are also working to identify potential strategic opportunities to leverage our growing global base of customers to accelerate shareholder value creation. For these and other reasons, we believe BIO-key is well-positioned for the future.”

Financial Results
Q1’24 revenues of $2.2M were in line with similarly strong Q1’23 revenues. The current-year period was positively impacted by the expanded use of BIO-key’s biometric client identification system by a long-time financial services customer in South Africa. One large order from this customer in Q1’24 was the primary driver of a 23.6% increase in license fee revenues, offset by a decline in recurring and custom services and hardware revenue. Services revenue decreased due to the loss of one large service agreement and the absence of a large customer for Swivel Secure customizations and upgrades, which had occurred in Q1’23.

Gross profit grew over 100% to $1.9M in Q1’24 from $0.9M in Q1’23, reflecting the impact of $0.5M hardware reserve in Q1’23, as well as higher software license fee costs in Q1’23 related to royalty payments resulting from higher sales of our third-party Swivel Secure offerings. As a result, gross profit margin improved to 86% in Q1’24 vs. 40% in Q1’23, which includes a hardware reserve expense. Q1’24 gross margin also increased due to a revenue mix that included more high-margin license fee revenue.

Total operating expenses were reduced by approximately $0.2M or 9%, to $2.4M in Q1’24 from $2.6M in Q1’23, due to lower selling, general and administrative costs (SG&A) and lower research, development and engineering expenses (RD&E). SG&A decreased $148,759 (8%) to $1.8M in Q1’24, due to reductions in administration, sales personnel costs and marketing show expenses, including lower lease expense for our NJ headquarters versus Q1’23, partially offset by higher audit and reporting expenses. In Q3 of 2023, we were able to downsize our corporate headquarters, as many of our team now work remotely, which benefitted Q1’24 vs. Q1’23. RD&E also declined by $82,638 (12%) to $607,521, due to reductions in personnel, related benefits and outside services expenses.

Reflecting revenue strength and lower operating costs, BIO-key trimmed its net loss by 70% to $510,285, or $0.32 per share, in Q1’24 from $1.7M, or $3.51 per share, in Q1’23.

Balance Sheet
At March 31, 2024, BIO-key had current assets of approximately $2.3M, including $690,449 of cash and cash equivalents, $710,026 of net accounts receivable and due from factor, and $440,194 of inventory.     

Conference Call Details

 

Date / Time:

Tuesday, June 18th at 10 a.m. ET

Call Dial In #:

1-877-418-5460 U.S. or 1-412-717-9594 Int’l

Live Webcast / Replay:

Webcast & Replay Link – Available for 3 months.

Audio Replay:

1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 1988012


About BIO-key International, Inc.
(www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission (“SEC”) and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

Engage with BIO-key

 

Facebook – Corporate:

https://www.facebook.com/BIOkeyInternational/

LinkedIn – Corporate:

https://www.linkedin.com/company/bio-key-international

Twitter – Corporate:

@BIOkeyIntl

Twitter – Investors:

@BIO_keyIR

StockTwits:

BIO_keyIR


Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800


BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2024

 

 

2023

 

Revenues

 

 

 

 

 

 

 

 

Services

 

$

213,122

 

 

$

532,522

 

License fees

 

 

1,950,434

 

 

 

1,578,556

 

Hardware

 

 

17,647

 

 

 

72,689

 

Total revenues

 

 

2,181,203

 

 

 

2,183,767

 

Costs and other expenses

 

 

 

 

 

 

 

 

Cost of services

 

 

138,849

 

 

 

154,801

 

Cost of license fees

 

 

148,221

 

 

 

620,881

 

Cost of hardware

 

 

12,573

 

 

 

44,592

 

Cost of hardware - reserve

 

 

-

 

 

 

500,000

 

Total costs and other expenses

 

 

299,643

 

 

 

1,320,274

 

Gross profit

 

 

1,881,560

 

 

 

863,493

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

1,782,973

 

 

 

1,931,732

 

Research, development and engineering

 

 

607,521

 

 

 

690,159

 

Total Operating Expenses

 

 

2,390,494

 

 

 

2,621,891

 

Operating loss

 

 

(508,934

)

 

 

(1,758,398

)

Other income (expense)

 

 

 

 

 

 

 

 

Interest income

 

 

5

 

 

 

4

 

Loss on foreign currency transactions

 

 

-

 

 

 

(15,000

)

Change in fair value of convertible note

 

 

-

 

 

 

141,991

 

Interest expense

 

 

(1,356

)

 

 

(56,919

)

Total other income (expense), net

 

 

(1,351

)

 

 

70,076

 

 

 

 

 

 

 

 

 

 

Loss before provision for income tax

 

 

(510,285

)

 

 

(1,688,322

)

 

 

 

 

 

 

 

 

 

Provision for (income tax) tax benefit

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(510,285

)

 

$

(1,688,322

)

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

Net loss

 

$

(510,285

)

 

$

(1,688,322

)

Other comprehensive income (loss) – Foreign currency translation adjustment

 

 

(62,275

)

 

 

72,146

 

Comprehensive loss

 

$

(572,560

)

 

$

(1,616,176

)

 

 

 

 

 

 

 

 

 

Basic and Diluted Loss per Common Share

 

$

(0.32

)

 

$

(3.51

)

 

 

 

 

 

 

 

 

 

Weighted Average Common Shares Outstanding:

 

 

 

 

 

 

 

 

Basic and diluted

 

 

1,615,323

 

 

 

480,833

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.


BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

 

(Unaudited)

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

690,449

 

 

$

511,400

 

Accounts receivable, net

 

 

701,776

 

 

 

1,201,526

 

Due from factor

 

 

8,250

 

 

 

99,320

 

Inventory

 

 

440,194

 

 

 

445,740

 

Prepaid expenses and other

 

 

427,685

 

 

 

364,171

 

Total current assets

 

 

2,268,354

 

 

 

2,622,157

 

Equipment and leasehold improvements, net

 

 

198,238

 

 

 

220,177

 

Capitalized contract costs, net

 

 

349,145

 

 

 

229,806

 

Operating lease right-of-use assets

 

 

23,220

 

 

 

36,905

 

Intangible assets, net

 

 

1,329,985

 

 

 

1,407,990

 

Total non-current assets

 

 

1,900,588

 

 

 

1,894,878

 

TOTAL ASSETS

 

$

4,168,942

 

 

$

4,517,035

 

 

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,212,071

 

 

$

1,316,014

 

Accrued liabilities

 

 

1,189,520

 

 

 

1,305,848

 

Government loan – BBVA Bank, current portion

 

 

135,835

 

 

 

138,730

 

Deferred revenue, current

 

 

755,405

 

 

 

414,968

 

Operating lease liabilities, current portion

 

 

23,797

 

 

 

37,829

 

Total current liabilities

 

 

3,316,628

 

 

 

3,213,389

 

Deferred revenue, long term

 

 

143,727

 

 

 

28,296

 

Deferred tax liability

 

 

22,998

 

 

 

22,998

 

Government loan – BBVA Bank – net of current portion

 

 

149,861

 

 

 

188,787

 

Total non-current liabilities

 

 

316,586

 

 

 

240,081

 

TOTAL LIABILITIES

 

 

3,633,214

 

 

 

3,453,470

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,814,414 and 1,032,777 of $.0001 par value at March 31, 2024 and December 31, 2023, respectively

 

 

181

 

 

 

103

 

Additional paid-in capital

 

 

126,092,496

 

 

 

126,047,851

 

Accumulated other comprehensive loss

 

 

(39,454

)

 

 

22,821

 

Accumulated deficit

 

 

(125,517,495

)

 

 

(125,007,210

)

TOTAL STOCKHOLDERS’ EQUITY

 

 

535,728

 

 

 

1,063,565

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

4,168,942

 

 

$

4,517,035

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.


BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 

 

 

Three Months Ended
March 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

CASH FLOW FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(510,285

)

 

$

(1,688,322

)

Adjustments to reconcile net loss to net cash used for operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

23,808

 

 

 

13,242

 

Amortization of intangible assets

 

 

78,005

 

 

 

81,237

 

Change in fair value of convertible note

 

 

-

 

 

 

(141,991

)

Amortization of capitalized contract costs

 

 

38,665

 

 

 

37,529

 

Reserve for inventory

 

 

-

 

 

 

500,000

 

Operating leases right-of-use assets

 

 

13,686

 

 

 

66,132

 

Share and warrant-based compensation for employees and consultants

 

 

47,790

 

 

 

59,373

 

Stock based directors’ fees

 

 

9,003

 

 

 

12,002

 

Bad debts

 

 

100,000

 

 

 

-

 

Change in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

399,749

 

 

 

(898,881

)

Due from factor

 

 

91,070

 

 

 

(33,000

)

Capitalized contract costs

 

 

(158,005

)

 

 

(8,739

)

Inventory

 

 

5,545

 

 

 

6,554

 

Prepaid expenses and other

 

 

(63,513

)

 

 

2,219

 

Accounts payable

 

 

(116,012

)

 

 

88,040

 

Accrued liabilities

 

 

(104,257

)

 

 

(135,417

)

Deferred revenue

 

 

455,868

 

 

 

178,755

 

Operating lease liabilities

 

 

(14,033

)

 

 

(67,544

)

Net cash provided by (used in) operating activities

 

 

297,084

 

 

 

(1,928,811

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Capital expenditures

 

 

(1,869

)

 

 

-

 

Net cash used in investing activities

 

 

(1,869

)

 

 

-

 

CASH FLOW FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Deferred offering costs

 

 

(13,470

)

 

 

-

 

Proceeds for exercise of warrants

 

 

1,400

 

 

 

-

 

Repayment of government loan

 

 

(41,821

)

 

 

(34,289

)

Net cash used in financing activities

 

 

(53,891

)

 

 

(34,289

)

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes

 

 

(62,275

)

 

 

49,913

 

 

 

 

 

 

 

 

 

 

NET DECREASE IN CASH AND CASH EQUIVALENTS

 

 

179,049

 

 

 

(1,913,187

)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

 

 

511,400

 

 

 

2,635,522

 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 

$

690,449

 

 

$

722,335

 

All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.


Advertisement